- 1 Efficacy and Safety of Chinese Herbal Injection Thoracic Perfusion
- 2 combined with Cisplatin chemotherapy for Lung Cancer Malignant
- 3 Pleural Effusion: A Systematic Review and Meta-Analysis
- 4 Zhong-Ning He<sup>1†</sup>, Ming-Wan Su<sup>1†</sup>, Jie-He<sup>1,2†</sup>, Guang-Hui Zhu<sup>1†</sup>, Yu-Wei Zhao<sup>1†</sup>, Shu-Lin He, <sup>1,2</sup>
- 5 Yue Li<sup>1,2</sup>, Bo-Lun Shi<sup>1</sup>, Jia-Qi Hu<sup>1,2</sup>, Shun-Tai Chen <sup>2\*</sup>, Bao-Jin Hua <sup>1\*</sup>
- 6 <sup>1</sup>Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- <sup>7</sup> <sup>2</sup>Beijing University of Chinese Medicine, Beijing, China
- 8 \* Correspondence:
- 9 Shun-Tai Chen, Bao-Jin Hua share co-correspondence
- 10 qdyc31236@163.com, huabaojinxs@126.com
- †Zhong-Ning He, Ming-Wan Su, Jie-He Guang-hui Zhu and Yu-Wei Zhao share co-first author.
- 12 **Purpose** To evaluate the efficacy and safety of Chinese herbal injection thoracic perfusion combined
- with cisplatin chemotherapy for lung cancer patients with MPE.
- 14 **Method** Eight databases were searched for articles published from inception to August 20, 2022 for
- randomized-controlled trials (RCTs) that are relevant. The included studies were reviewed by two
- 16 investigators, with relevant data extracted independently. Primary outcome was identified as
- objective response rate (ORR), while secondary outcomes were identified as quality of life (QOL)
- and adverse reactions. Quality of the included trials was assessed through risk of bias assessment of
- the Cochrane risk-of-bias tool. The Revman 5.3 and Stata 17.0 software were used to calculate risk
- 20 ratio (RR) at 95% confidence intervals (CI) for binary outcomes.

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

**Results** 29 RCTs involving 1887 patients were included in this study. Compared with patients treated with cisplatin thoracic perfusion alone, those with Chinese herbal injection and cisplatin thoracic perfusion had better therapeutic effects (RR=1.44, 95% CI: 1.35~1.53, P = 0.000), higher KPS score  $(RR = 1.47, 95\%CI: 1.34\sim1.61, P = 0.0000)$ , lower digestive tract reaction  $(RR = 0.56, 95\%CI: 1.34\sim1.61, P = 0.0000)$  $0.48 \sim 0.67$ , P = 0.000), bone marrow suppression (RR = 0.50, 95% CI: 0.43 $\sim$ 0.59, P =0.000) and chest pain reactions (RR = 0.65, 95%CI:  $0.47\sim0$ . 89, P = 0.007). **Conclusion** The systematic review indicated that Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy may improve therapeutic effect, quality of life, and reduce adverse reactions. More large-scale and higher quality RCTs are warranted to support our findings. Systematic Review Registration: PROSPERO, identifier CRD42022347345. **Keywords:** Chinese Herbal, lung cancer, malignant pleural effusion, cisplatin, thoracic perfusion. systematic review, meta-analysis Introduction 1 Lung cancer is one of the most common malignant tumors in the world, with high morbidity and mortality<sup>[1]</sup>, Malignant Pleural Effusion (MPE) is a common complication in lung cancer patients. and the median survival time is only 5.5 months<sup>[2]</sup>. The occurrence of MPE is associated with poor quality of life (QOL) and shorter survival time in lung cancer patients<sup>[3]</sup>. Thus, effective treatment for MPE appears very important. The main purpose is to control the effusion from growth, relieve dyspnea, improve the quality of survival, to extend the survival. Currently, management options for MPE includes chest tube drainage and systematic chemotherapy to achieve symptomatic relief and controlling the primary malignancies. Thoracic perfusion of chemotherapeutic is an effective method for the treatment of MPE, and thoracic perfusion of cisplatin has good pharmacodynamics<sup>[4,5]</sup>, high economic practicability<sup>[6]</sup>. However, the side effects of cisplatin, such as gastrointestinal reactions

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

and hepatorenal toxicity, cannot be ignored, and will affect the quality of life of patients to a certain extent<sup>[7]</sup>. Therefore, current management approach remain palliative. Thus, we seek to find an effective combined treatment for MPE. In recent years, related studies have shown that anti-tumor Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy in the treatment of MPE have a positive effect in improving efficiency, improve the quality of life, reduce adverse reactions<sup>[8-10]</sup>. Although the clinical studies on Chinese herbal injection in the treatment of lung cancer MPE are increasing, the long-term efficacy has not been measured. Lack of high quality, neat standard clinical research, In order to obtain higher evidence data, this study using evidence-based medicine method, comprehensive collection published in Chinese and English literature at present, the systematic evaluation of Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy of lung cancer MPE, curative effect in order to provide a basis for evidence based medicine in the future clinical treatment. 2 **METHODS** This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines<sup>[11]</sup>. The protocol has been registered in PROSPERO (registration number: CRD42022347345). 3 **Search strategy** An independent review of citations was searched for articles published from inception to August 20, 2022, relevant publications evaluating the efficacy and safety of Chinese herbal injection for Lung cancer with MPE were searched in the Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, the VIP Information Database, Chinese Biomedical Literature database (CBM), PubMed, EMBASE, and the Cochrane Library. The following Key words were used: "Lung Neoplasms OR Lung Cancer" AND "Pleural Effusion, Malignant OR Malignant Pleural Effusion" AND "Cisplatin"

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

AND "Elemene injection OR Kushen injection OR Kanglaite injection OR Brucea Javanica oil emulsion OR Yuxingcao injection OR Aidi injection OR Xiao-ai-ping injection OR Huachansu injection OR Shenqifuzheng injection OR Kang-Ai injection OR Kushenhuangqi injection". All retrievals were implemented using MeSH and free words (the detailed search strategy is available in Supplementary 1). The languages were restricted to Chinese and English. 4 Study selection and data extraction Eligible studies were randomized controlled trials of lung cancer adults (≥18) with MPE involvingChinese herbal injection thoracic perfusion combined with cisplatin chemotherapy comparing to cisplatin thoracic perfusion alone. We defined intervened injections as Elemene injection, Kushen injection, Kanglaite injection, Brucea Javanica oil emulsion, Yuxingcao injection, Aidi injection, Xiao-ai-ping injection, Huachansu injection, Shengifuzheng injection, Kang-Ai injection, Kushenhuangqi injection etc. Studies were excluded if patients were treated with other chemotherapy. Two reviewers Ming-Wan Su and Jie-He independently selected studies based on the inclusion and exclusion criteria described above. Two reviewers independently extracted details for each trial: first author name and year of publication, patient characteristics; Intervention: Chinese herbal injection, Cisplatin ingredients, dose, treatment time; primary and secondary outcome measures. Missing information can be obtained by contacting the author. 5 Data synthesis and analysis The primary outcome measure is objective remission rate (ORR) of MPE which was defined as CR + PR<sup>[12]</sup>. Quality of life (QOL) evaluated with Karnofsky score. Adverse events (digestive tract reactions, bone marrow suppression, chest pain) are second outcome measures. The data were processed and analyzed by Stata 17.0 (Stata Corp, College Station, SE). Random-effects models were

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

performed to calculate pooled effects. Fixed-effect models were performed if statistical heterogeneity was absent (heterogeneity test,  $P \ge 0.10$ ), dichotomous data were presented as pooled Risk Ratio (RR) with 95% confidence intervals (95% CIs), Assessment of heterogeneity was performed using Cochran's Q test and Higgins's  $I^2$ ;  $I^2 > 50\%$  and a P value < 0.10 suggested significant heterogeneity<sup>[13]</sup>. Sensitivity analysis was performed by sequentially omitting each study to examine the robustness of the results. Potential publication bias was evaluated using Begg's funnel plot and Egger's test<sup>[14]</sup>. 6 **Risk of Bias Assessment** Two reviewers Zhong-Ning He and Guang-Hui Zhu independently assessed the quality of the selected trials according to the RCT trials tool of the Cochrane Collaboration. Items were divided into three categories: low risk bias, unclear bias and high-risk bias. The following features are random sequence generation (selection bias), concealment of assignment (selection bias), blinding of participants, personnel (performance bias), outcome data were incomplete (attrition bias), selective reporting (reporting bias), and other bias. These assessments are plotted and evaluated using Review Manager 5.3. Result 7 7.1. Search Result Initially 281 literatures from 7 electronic databases were identified. After the removal of 98 duplications and 55 irrelevants after screening through the title and abstract, 43 articles were consider potentially appropriate for inclusion. Among which, 14 articles were excluded for the following reasons: not lung cancer patient (n=2), not thoracic perfusion (n=4), Chinese herbal injection intervention alone (n=6), Chinese herbal injection with other chemotherapy (n=2). Eventually, 29

single-centered RCTs met all inclusion criteria,<sup>[8-10, 15-40]</sup> as shown in the flow diagram (Locate Figure 113 1)

## Figure 1 Flow diagram

### 7.2. Characteristics of the Included Studies

All 29 studies yielded a total of 1,887 patients. The baseline characteristics of each trial are presented in Table 1. The control group was treated with cisplatin thoracic perfusion, on the basis of the control group, the experimental group was infused with chinese herbal injection. 29 trials reported the ORR following WHO guidelines, KPS was reported in 16 studies, and adverse events were reported in 24 studies, Among the 29 citations, intervention of experimental group was Aidi injection in 12 studies[10, 18, 21, 24, 26, 30-32, 35-38], Kushen injection in 10 studies[8, 16, 17, 20, 22, 25, 27, 33, 34, 40], Brucea Javanica oil emulsion in 3 studies[9, 29, 39], and other injections were not included because less than 3 studies. A total of 16 studies reported QOL improvement (the number of patients KPS score 10 points higher or stable after treatment)[8, 9, 15, 16, 21, 22, 24-27, 29, 33, 34, 36, 37, 39]. 24 studys that included 1,527 patients reported adverse reactions[8, 9, 16-27, 29, 31-39]. Bone marrow suppression was recorded in 23 studies[8, 9, 16-21, 23-27, 29-32, 34-39, 41]. 19 studys that included 1,353 patients reported chest pain[9, 15, 16, 18-24, 26, 29, 31-33, 35, 37-39]

### **Table1** Characteristics of the Included Studies

Einst	IZ.			Г		Interv	
First	K			E Chinese Herbal	cisplatin	entio	Outco
author,	P	Years	M/F	/ Injection	(DDD)	10	<b>100</b> 0.0
year	S			Injection C	(DDP)	n	mes
						time	

				3 Brucea Javanica			
Wang, HM.20 07	> 5 0	26~81	45/2 5	5 oil  / emulsion,80~100  3 ml,5~7d/c,4cycle  5 s	20~30mg/m², 5~7d/c,4cycle s	30da y	O1,2, 3,4,5
Hu,JC. 2008	> 5 0	65±15 /62±1 7	43/2	3 6 Kushenhuangqi / injection,60ml,7 3 d/c,4cycles 5	40mg/m <sup>2</sup> ,7d/c ,4cycles	30da y	O1,3, 4,5
Yao,Y W.200 8	<b>≧</b> 6 0	38 ~ 85	33/1	2 3 Aidi / injection,100ml/ 2 d,7d/c,4cycles 3	30mg/d,7d/c, 4cycles	28da y	O1,2, 3,4,5
Li,YP. 2009	-	35~70	49/1 1	3 0 Kushen / injection,20ml,7 3 d/c,4cycles 0	40mg,7d/c,4c ycles	28da ys	O1,3, 4,5

Zhang, SF.200	> 5 0	65~80	35/1	2 Brucea Javanica 7 oil / emulsion,50~100 2 ml,5~7d/c,4cycle 3 s	20~30mg/m², 5~7d/c,4cycle s	30da ys	O1,2, 3,4,5
Meng,S L.2009	> 5 0	58~79	28/1	2 2 Aidi / injection,50~80 2 ml,7d/c,4cycles 0	20~30mg/m², 7d/c,4cycles	30da ys	O1,2, 3,4,5
He,L.2 010	-	39~75	25/1 9	2 4 Kushen / injection,40ml,7 2 d/c,3cycles 0	40mg/m <sup>2</sup> ,7d/c ,3cycles	21da ys	O1,2, 4
Wang, XH.20	-	20~69	47/1	3 0 Aidi / injection,50ml,7 3 d/c,4cycles 0	40mg,7d/c,4c ycles	28da ys	O1,4

Han,Z Q.2012	> 5 0	41~91	35/2	2 8 Kushen / injection,20mg,7 2 d/c,2~4cycles 8	20~40mg,7d/ c,2~4cycles	28da ys	O1,2, 3,4,5
Sun,SL .2012	> 5 0	43~74	27/1	2 1 Aidi / injection,50~80 1 ml,7d/c,4cycles 9	20~30mg/m², 7d/c,4cycles	28da ys	O1,2, 3,4,5
Liu,CX .2013	> 4 0	41~82	57/5 5	<ul> <li>5</li> <li>6 Aidi</li> <li>/ injection,100ml,</li> <li>5 7d/c,4cycles</li> <li>6</li> </ul>	30mg,7d/c,4c ycles	28da ys	O1,2, 3,4,5
Wang, XC.201	_	29~83	46/1 8	3 2 Aidi / injection,40ml,7 3 d/c,4cycles 2	60mg,7d/c,4c ycles	28da ys	O1,3, 4,5

Liu,D.2 015	> 6 0	60.2± 8.2	48/4	4 6 Kushen / injection,20ml,7 4 d/c,3cycles 2	40 ~ 60mg,7d/c,3c ycles	30da y	O1,2, 3,5
Yang,D F.2015	> 4 5	41~76	33/1	2 5 Aidi / injection,75ml/d, 2 7d/c,5cycles 5	25mg/d,7d/c, 5cycles	35da ys	O1,2, 3,4
Wang, HX.20 16	-	64.5± 8.7	44/2	3 5 Kushenhuangqi / injection,60ml,5 3 ~7d/c,4cycles 5	40mg/m2,5~7 d/c,4cycles	28da ys	O1
Liu,L.2 017	≥ 5 0	32~76	-	3 0 Kushen / injection,20ml,7 3 d/c,4cycles 0	40mg,7d/c,4c ycles	28da ys	O1,2, 3,4

Liu,SY .2017	> 6 0	33~78	35/2 9	3 2 Huachansu / injection,20ml,7 3 d/c,2cycles 2	40mg,7d/c,2c ycles	30da ys	O1,3, 4,5
Shen,S L.2017	<b>≧</b> 6 0	48~70	52/2 8	Brucea Javanica  o oil  emulsion,50ml,7  d/c,4cycles  o	50mg/m <sup>2</sup> /d,7 d/c,4cycles	28da ys	O1,2, 3,4,5
Shi,WJ .2017	≥ 5 0	34 ~ 78	39/2	3 0 Kushen / injection,20ml,7 3 d/c,4cycles 0	40mg,7d/c,4c ycles	28da ys	O1,2, 3,4
Hou,TJ ,2017	> 4 5	18~80	52/3 8	4 5 Aidi / injection,100ml, 4 7d/c,4cycles 5	30mg,7d/c,4c ycles	28da ys	O1,3, 4,5

Shi,WL2017	30 ~ 80	20/1	1 5 Aidi / injection,40ml,7 1 d/c,4cycles 5	60mg,7d/c,4c ycles	28da ys	01
Wang, - Y.2017	44 ~ 72	45/1 9	3 2 Aidi / injection,50~80 3 ml,7d/c,4cycles 2	20~30mg/m², 7d/c,4cycles	28da ys	O,3,4 ,5
Chen,F - .2018	35 ~ 67	76/7 4	<ul> <li>7</li> <li>5 Elemene</li> <li>/ injection30mg,1d</li> <li>7 /c,14cycles</li> <li>5</li> </ul>	50mg,1d/c,14 cycles	14da y	O1,2,
Tang,X - Q.2018	33 ~ 77	-	3 0 Kushen / injection,60ml,3 3 d/c,6cycles 0	40mg,3d/c,6c ycles	21da ys	O1,2, 3,4

Zhu,X. 2018	36~75	27/2	2 5 Kushen / injection,20ml,7 2 d/c,3cycles	60mg,7d/c,3c ycles	28da ys	01
Wang, - Y.2019	58~75	49/4 1	4 5 Kushen / injection,20ml,7 4 d/c,3cycles 5	40 ~ 60mg,7d/c,3c ycles	21da ys	O1,2, 3,5
Wu,CY - .2019	39 ~ 68	30/2	2 Kushen 5 injection,40~60 / ml,3~7d/c,4cycle 2 s 5	_	30da ys	O1,2, 3,4
Wu,M B.2020	50 ~ 78	25/1 1	1 Aidi 8 injection,50ml/d, 7d/c,12~ 1 8 18cycles	25mg/d,7d/c, 12 ~ 18cycles	126d ay	O1,3, 4,5

**Note:** M/F, male/female; KPS, Karnofsky score; E/C, experimental group/control group; O, 130 outcomes; O1, objective response rate (ORR); O2, Quality of Life (QOL); O3, Digestive tract reaction; O4, Bone marrow suppression; O5, Chest pain

### 7.3. Study quality and Risk of bias

129

131

132

133

134

135

136

137

138

139

140

141

142

143

Among all studies included, 24 used random assignment<sup>[8-10, 15-17, 19-29, 31, 32, 34-36, 38, 39]</sup>, and seven of them reported the way assignments were hidden<sup>[15, 19, 22, 25, 31, 32, 35]</sup>. In terms of blind implementation, none of the studies mentioned it. Two of the included studies may have had incomplete data records, which have no effect on the results of the study [20, 40], for reasons not explained in the report. In terms of selective reporting of outcomes, all studies reported treatment from two or more aspects, with a low risk of reporting bias. In terms of other biases, 2 treatment methods of the experimental groups were not exclusively described in 2 studies, which may have other biases<sup>[15, 38]</sup>. Figure 2 shows more details. (LocateFigure2)

**Figure 2** Risk of bias summary and diagram. (A) Risk of bias summary. (B) Risk of bias diagram.

### 7.4. Primary outcomes

### 7.4.1 Objective Remission Rate (ORR)

144 Comparing to cisplatin thoracic perfusion, the ORR favored Chinese herbal injection group

145 (RR=1.44, 95% CI: 1.35~1.53, 
$$P = 0.000$$
;  $I^2 = 38.4\%$ ,  $P = 0.020$ ). (LocateFigure 3)

- 146 **Figure 3** forest plot of ORR
- 147 7.5. Secondary outcomes
- 148 **7.5.1 Quality of Life (QOL)**
- 149 Compared with cisplatin thoracic perfusion alone, Chinese herbal injection thoracic perfusion
- 150 combined with cisplatin chemotherapy could significantly improve the KPS scores (RR = 1.47,
- 95%CI: 1.34 $\sim$ 1.61, P = 0.0000), with low heterogeneity ( $I^2 = 0\%$ , P = 0.943), and there was a
- statistical difference between the two groups. (LocateFigure 4)
- 153 **Figure 4** Meta-analysis of QOL
- 154 **7.5.2 Digestive tract reaction**
- 155 Comparing to cisplatin thoracic perfusion, Chinese herbal injection thoracic perfusion combined with
- cisplatin chemotherapy significantly reduced the incidence of digestive tract reactions (RR = 0.56,
- 95%CI:  $0.48 \sim 0.67$ , P = 0.000) with low heterogeneity ( $I^2 = 27.5\%$ , P = 0.106). (LocateFigure 5)
- 158 **Figure 5** | Meta-analysis of digestive tract reaction
- 159 **7.5.3 Bone marrow suppression**
- The incidence of bone marrow depressions in experimental group was significantly ower than that in
- 161 control group (RR = 0.50, 95% CI: 0.43 $\sim$ 0.59, P = 0.000) with low heterogeneity ( $I^2$  = 8.9%, P =
- 162 0.340). (LocateFigure 6)
- 163 **Figure 6** Meta-analysis of bone marrow suppression
- 164 **7.5.4** Chest pain
- The experimental group significantly reduced the incidence of chest pain reactions (RR = 0.65,
- 95%CI:  $0.47 \sim 0.89$ , P = 0.007), with low heterogeneity ( $I^2 = 0\%$ , P = 0.631). (LocateFigure 7)

# Figure 7 | Meta-analysis of Chest pain

### 7.6 Subgroup analysis of QOL and Adverse reactions

Among the 5 secondary outcome measures, subgroup analysis was performed according to the difference of Chinese herbal injections. The results of subgroup analysis are shown in Table 2. Compared with cisplatin thoracic perfusion alone, Aidi injection, Kushen injection, Brucea Javanica oil emulsion combined with cisplatin thoracic perfusion in the treatment of MPE has a better therapeutic effect in QOL, digestive tract reaction, and bone marrow suppression outcome, and the differences are statistically significant, the results of subgroup analysis were consistent with the trend of the overall combined results. But there was no statistically significant difference in the outcome index of chest pain, which was different from the overall combined trend. (Table2)

Table 2 results of subgroup analysis

Outcome	Pooled	Z	Р	Heterogeneity	
	RR(95%CI)				
				<i>P</i> (%)	$P_{h}$
Quality of	1.52(1.37,1.69)	8.05	0.000	0%	0.998
Life (QOL)					
Digestive	0.53(0.43,0.64)	6.37	0.000	27.9%	0.111
tract					
reaction					

Bone marrow	0.52(0.44,0.61)	7.60	0.000	8.6%	0.346
suppression					
Chest pain	0.82(0.54,1.25)	0.93	0.35	0%	0.729

### 7.7 Moderator effects

To investigate the sources of potential heterogeneity, we conducted subgroup analysis with moderator variables include injection categories, According to the results of subgroup analysis in Figure 8, it can be concluded that Aidi injection combined with cisplatin thoracic perfusion (RR=1.37, 95%CI:  $1.25\sim1.50$ , P=0.000,  $I^2=58.3\%$ , P=0.006), Kushen injection combined with cisplatin thoracic perfusion (RR = 1.48, 95%CI:  $1.32\sim1.66$ , P=0.000,  $I^2=0\%$ , P=0.813). Brucea Javanica oil emulsion combined with cisplatin thoracic perfusion was infused into the chest (RR = 1.68, 95%CI:  $1.34\sim2.09$ , P=0.000,  $I^2=0\%$ , P=0.964). Compared with cisplatin thoracic perfusion alone, all of them have more effective rate in the treatment of MPE, and the difference is statistically significant. Therefore, the results of the subgroup analysis on ORR, the primary outcome measure, were trend consistent with the overall pooled results (RR = 1.45, 95%CI:  $1.35\sim1.55$ , P=0.000,  $I^2=45.2\%$ , I=0.008). (LocateFigure8)

## Figure 8 | Subgroup analysis of ORR

#### 7.8 Sensitivity analysis

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

In this study, sensitivity analysis was conducted leave-one-out method, revealing that Hou TJ<sup>[18]</sup> had a rather great impact on heterogeneity. After the elimination, I<sup>2</sup> decreased from 38.4% to 0%, but had little effect on the final results (RR=1.44, 95% CI: 1.35~1.53, P = 0.000 vs RR:1.47, 95%CI: 1.37 $\sim$ 1.56, P = 0.0000). There was a certain heterogeneity in subgroup analysis of ORR ( $I^2 = 45.2\%$ ). After deleting the study of Hou  $TJ^{[18]}$ ,  $I^2$  decreased from 45.2% to 0%, but had little effect on the final results (RR = 1.42, 95%CI: 1.30 $\sim$ 1.55, P = 0.000 vs RR:1.40, 95%CI: 1.31 $\sim$ 1.50, P = 0.0000). (Figure 9A-B). Compared with other research, Hou TJ had a relatively high response rate, so as to tilting the heterogeneity much heavier. For second outcome: Quality of life (QOL), digestive tract reaction, bone marrow suppression and chest pain, outcome indicators found that the heterogeneity among studies was small ( $I^2 < 30\%$ ), and the inclusion of one study by one had little impact on the results, so these results were stable (LocateFigure 9). **Figure 9** (A) sensitivity analysis of ORR; (B) sensitivity analysis of Subgroup analysis of ORR; (C) sensitivity analysis of QOL; (D) sensitivity analysis of digestive tract reaction; (E) sensitivity analysis of bone marrow suppression; (F) sensitivity analysis of chest pain 7.9 Publication bias Funnel plots were drawn according to the primary outcome measure ORR, we noticed that the included study was distributed asymmetrically on both sides of the funnel chart (Figures 10A–C), indicating that there was significant publication bias in the meta-analysis. The Begg (p=0.003) and Egger (p=0.000) test was used to test the publication bias of 29 studies included in this meta-analysis, and the results showed that this study had obvious publication bias (P<0.05). The 29 articles included in this study were analyzed by the trim-fill method, and the results showed that after the inclusion of 14 virtual studies, Meta-analysis was conducted again, using the fixed effect model, and the combined results of effect indicators RR=1.229, 95%CI:1.171~1.289, although some small sample

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

studies were added to correct the publication bias, which did not have a significant impact on the results. (LocateFigure 10) Figure 10 | (A) Funnel plot of ORR; (B) Egger test of ORR; (C) Begg test of ORR; (D) trim-fill method of ORR 8 **Discussion** The aim of this meta-analysis is to evaluate the efficacy and safety of Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy in the treatment of lung cancer MPE. Compared with the published meta-analysis<sup>[42]</sup>, our study is the first to control the administration mode of traditional Chinese herbal injection as thoracic perfusion, using thoracic perfusion of cisplatin as the control group, which ensures the consistency of intervention measures and can reduce clinical heterogeneity to a certain extent. Our results demonstrated that Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy can improve the ORR of lung cancer patients with MPE (RR=1.44, 95% CI: 1.35 $\sim$ 1.53, P = 0.000). In addition, we also performed subgroup analysis according to different Chinese herbal injection. The results showed that compared with cisplatin thoracic perfusion alone, Aidi injection, Kushen injection and Brucea Javanica oil emulsion could improve the ORR of lung cancer patients with MPE. As we all know, lung cancer patients with MPE will have symptoms of chest pain due to poor water circulation. Chemotherapy drugs will inhibit the hematopoietic function of bone marrow, and also affect the digestive function of patients, with vomiting, diarrhea and other digestive tract reactions, further affecting the quality of life of patients. In terms of quality of life, our results showed that Chinese herbal injection could effectively improve the quality of life of patients with lung cancer MPE, and the results of subgroup analysis were consistent with the total results. In addition, Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy can effectively improve the

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

digestive tract reaction and bone marrow suppression of patients, and the results are statistically significant and consistent with the results of subgroup analysis. Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy can alleviate chest pain in patients, but the results of subgroup analysis showed no statistical significance, which may be related to the small sample size included in the study. We should consider focusing on this adverse reaction in the future. Although funnel plots for the 29 studys showed that there was significant publication bias in the meta-analysis, there is no significant difference between the results of trim-fill method and the original data, which is favorable to our existing results Our study also have certain limitations, which increase the risk of bias in the outcome indicators of this study. First of all, although this study adopted a relatively extensive search strategy, some conference papers, supplements and grey literature may not be fully obtained, so potential publication bias cannot be excluded. The funnel plot and Begg and Egger test results also reflect some potential publication bias. Among the 29 included studies, only 7 studies described the method of randomization, while the remaining studies did not explain the method of randomization and allocation concealment, and no study mentioned the blinding method, which may lead to potential performance bias and selection bias. Secondly, the sample size of all the included studies was generally small, and the efficacy of the subjects was not tracked. The intervention measures, intervention time and drug administration plan of all the studies were not completely unified, and the forms and effectiveness of the intervention mechanisms could not be clarified. It may increase the imprecision of the outcome indicators and make the evidence strength of the outcome indicators low. Finally, important clinical survival outcomes such as overall survival, progression-free survival, and 5-year survival were not fully reported in the included studies. Therefore, high quality and large sample clinical studies are needed in the future to further evaluate the efficacy and safety of Chinese

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

herbal injection thoracic perfusion combined with cisplatin chemotherapy in the treatment of lung cancer MPE, and provide more evidence to support our findings. 9 Conclusion Our study demonstrated the potencies of Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy to enhance the efficacy and safety for lung cancer MPE patients, improve quality of life and decrease adverse reactions. Furthermore, the long-term efficacy of Chinese herbal injection in Lung cancer MPE treatment still needs to be verified in future well-designed clinical trials that adhere to CONSORT guidelines. More efforts are needed to promote the application of Chinese herbal injection in the clinic. **Acknowledgments** We sincerely thank all support from all authors. **Funding Statement** This study was supported by National Natural Science Foundation of China (82174465). **Data Availability** The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request Reference 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. Epub 2021/02/05. doi: 10.3322/caac.21660. PubMed PMID: 33538338. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer


patients with pleural effusions. Respirology. 2015;20(4):654-9. Epub 2015/02/24. doi: 10.1111/resp.12496.


- 283 PubMed PMID: 25706291.
- Ryu JS, Ryu HJ, Lee SN, Memon A, Lee SK, Nam HS, et al. Prognostic impact of minimal pleural
- 285 effusion in non-small-cell lung cancer. J Clin Oncol. 2014;32(9):960-7. Epub 2014/02/20. doi:
- 286 10.1200/jco.2013.50.5453. PubMed PMID: 24550423.
- Lerza R, Vannozzi MO, Tolino G, Viale M, Bottino GB, Bogliolo G, et al. Carboplatin and cisplatin
- pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Ann Oncol.
- 289 1997;8(4):385-91. Epub 1997/04/01. doi: 10.1023/a:1008203100410. PubMed PMID: 9209670.
- 290 5. Sakaguchi H, Ishida H, Nitanda H, Yamazaki N, Kaneko K, Kobayashi K. Pharmacokinetic evaluation
- of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural
- 292 effusion. Lung Cancer. 2017;104:70-4. Epub 2017/02/19. doi: 10.1016/j.lungcan.2016.12.015. PubMed PMID:
- 293 28213004.
- 294 6. Xia Y, Fang P, Zhang X, Su G, Shen A. The efficacy of Endostar combined with platinum pleural infusion
- for malignant pleural effusion in tumor patients is significantly better than that of monotherapy, but the economy
- is lower: a systematic review, network meta-analysis and cost-effectiveness analysis. Ann Transl Med.
- 297 2022;10(10):604. Epub 2022/06/21. doi: 10.21037/atm-22-2091. PubMed PMID: 35722417; PubMed Central
- 298 PMCID: PMCPMC9201148.
- 299 7. Zhong LZ, Xu HY, Zhao ZM, Zhang GM, Lin FW. Comparison of efficacy and toxicity between nedaplatin
- and cisplatin in treating malignant pleural effusion. Onco Targets Ther. 2018;11:5509-12. Epub 2018/09/21. doi:
- 301 10.2147/ott.S168391. PubMed PMID: 30233211; PubMed Central PMCID: PMCPMC6134960.
- 302 8. Liu LZ, SS. Li,GM. Effects and safety of compound Kushen injection combined with cisplatin on
- 303 malignant pleural effusion. J Mod Oncol Mod Oncol Hsien Tai Chung Liu Hsueh. 2017;25(02):230-3. doi:
- 304 10.3969/j.issn.1672-4992.2017.02.018.
- 305 9. Shen S. Clinical Effect of Cisplatin Combined with Brucea Javanica Oil Emulsion in Treating Malignant
- Pleural Effussion Caused by Lung Cancer. Chinese Journal of Clinical Rational Drug Use. 2017;10(30). doi: 10.
- 307 15887 /j. cnki. 13-1389 /r. 2017. 30. 005.
- 308 10. Shi W. Effect of Intrapleural Injection of Addie and Cisplatin in the Treatment of Malignant Pleural
- 309 Effusion and Malignant Pleural Effusion. China Continuing Medical Education. 2017;9(20):187-9. doi:
- 310 10.3969/j.issn.1674-9308.2017.20.100.
- 311 11. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for
- 312 systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. Epub
- 313 2015/01/03. doi: 10.1186/2046-4053-4-1. PubMed PMID: 25554246; PubMed Central PMCID:
- 314 PMCPMC4320440.
- 315 12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer.
- 316 1981;47(1):207-14. Epub 1981/01/01. doi: 10.1002/1097-0142(19810101)47:1<207::aid-
- 317 cncr2820470134>3.0.co;2-6. PubMed PMID: 7459811.
- 318 13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical
- 319 test. Bmj. 1997;315(7109):629-34. Epub 1997/10/06. doi: 10.1136/bmj.315.7109.629. PubMed PMID: 9310563;
- 320 PubMed Central PMCID: PMCPMC2127453.


- 321 14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj.
- 322 2003;327(7414):557-60. Epub 2003/09/06. doi: 10.1136/bmj.327.7414.557. PubMed PMID: 12958120; PubMed
- 323 Central PMCID: PMCPMC192859.
- 324 15. Chen FY, HS. Cheng, D. Li, J. Clinical Efficacy and Prognosis of Kingkong Elemene Liposomal Imection
- 325 Combined with Cisplatin for Malignant Pleural Effusion of Lung Cancer. The Practical Journal of Cancer.
- 326 2018;33(07):1169-71. doi: 10.3969/j.issn.1001-5930.2018.07.036.
- 327 16. Han ZT, MQ. Chen, XP. Shi, F. Effect of Closed Drainage Combined with Compound Kushen Injection
- and Cisplatin on Malignant Pleural Effusion of Lung Cancer. Zhejiang Journal of Integrated Traditional Chinese
- 329 and Western Medicine. 2012;22(07):524-6. doi: 10.3969/j.issn.1005-4561.2012.07.011.
- He L, Chen Z, Wen S, Ren D, Chen H. Compound Kushen Injection as a Local Therapy for Patients
- with Advanced Lung Cancer Associated with Malignant Pleural Effusion. Evaluation and Analysis of Drug-Use in
- Hospitals of China. 2010;10(11):1025-7. doi: 10.14009/j.issn.1672-2124.2010.11.012.
- 333 18. Hou T. Clinical Effect Analysis of Aidi Injection and Cisplatin in the Treatment of Lung Cancer
- 334 MalignantPleural Effusion. Journal of North Pharmacy. 2017;14(01):178-9. doi: 10.3969/j.issn.1672-
- 335 8351.2017.01.152.
- Hu JL, QQ. Xie,YS. Intrathoracic administration of Kushenhuangqi Injection combined with cisplatin in
- treatment of malignant pleural effusion. Chinese Journal of General Practitioners. 2008;7(8). doi:
- 338 10.3760/cma.j.issn.1671-7368.2008.08.027.
- 20. Li YC, Cp. Li,Qy. Treatment of Lung Cancer Malignant Pleural Effusion with Compound Kushen Injection
- 340 Combined with Cisplatin. China's Naturopathy. 2009;17(04):42. doi: 10.19621/j.cnki.11-3555/r.2009.04.043.
- 341 21. Liu CP, LY. Zhou,B. The Curative Effect of Addie Injection of Traditional Chinese Medicine combined
- with Cisplatin on the Treatment of Lung Cancer with Hydrothorax. World Chin Med Shih Chieh Chung I Yao.
- 343 2013;8(12):1425-7. doi: 10.3969/j.issn.1673-7202.2013.12.014.
- 22. Llu D, Ll D. Curative effect and nursing of thoracic cavity drainage and compound kushen injection
- combined with cisplatin in the treatment of lung cancer patients companying with malignant pleural effusion. J
- 346 Clin Med Pract Shih Yung Lin Ch'uang I Yao Tsa Chih, 2015;19(08);21-4, doi: 10.7619/icmp.201508007.
- Liu SM, XJ, Shan B, Li Y, Wang S, Chang N, Fu W. Observation of Clinical Efficacy on Malignant Pleural
- 348 Effusion Treated with Cinobufacini Injection and Cisplatin by Intracavitary Perfusion. Chinese Journal of Coal
- 349 Industry Medicine. 2017;20(07):791-4. doi: 10.11723/mtgyyx 1007-9564 201707010.
- 350 24. Meng S. Clinical Study of Aidi Injection Combined with Cisplatin in the Treatment of Lung Cancer
- 351 Malignant Pleural Effusion. China Practical Medicine. 2009;4(21):167-8. doi: 10.3969/j.issn.1673-
- 352 7555.2009.21.119.
- 353 25. Shi W. Clinical Eficacy and Safety of Compound Matrine Injection Combined with Cisplatin in the
- 354 Treatment of Malignant Pleural Effusion Caused by Lung Cancer. Chinese Journal of Convalescent Medicine.
- 355 2017;26(08):857-9. doi: 10.13517/j.cnki.ccm.2017.08.032.
- 356 26. Sun SL, M. Clinical Study of Aidi injection Combined with Cisplatin in the Treatment of Lung Cancer
- 357 Malignant Pleural Effusion. Mod J Integr Tradit Chin West Med Hsien Tai Chung Hsi I Chieh Ho Tsa Chih.
- 358 2012;21(21):2317-8. doi: 10.3969/j.issn.1008-8849.2012.21.018.


- 359 27. Tang XJ, MH. Li, JP. Luo, BP. Cinical Objective on Sixty Cases of Compound Kushen Injection Combined
- 360 with Cisplatin in Treatment of Lung Cancer Pleural Effusion. Liaoning Journal of Traditional Chinese Medicine.
- 361 2018;45(08):1668-70. doi: 10.13192/j.issn.1000-1719.2018.08.036.
- 362 28. Wang H. Intrathoracic administration of Kushenhuangqi Injection combined with cisplatin in treatment
- of malignant pleural effusion. Clinical Research. 2016;24(6).
- Wang HL, GQ. Liu, PH. Qu, YM. Xie, GQ. Liu, SX. Brucea Javanica Oil Emulsion Injection Combined with
- Chain in the Treatment of Lung Cancer Malignant Pleural Effusion. Mod Chin Med Chung-kuo Hsien Tai Chung
- 366 Yao. 2007;9(2). Epub 20131012. doi: 10.3969/j.issn.1673-4890.2007.02.009.
- 367 30. Wang X. Clinical Observation of Aidi Injectio Combined with Cisplatin in the Treatment of Lung Cancer
- 368 Malignant Pleural Effusion. China Health Care. 2010;(3). Epub 20101130.
- 369 31. Wang X. Effect of Aidi Injection Combined with Cisplatin on Intrathoracic Perfusion in Patients with Lung
- Cancer Complicated with Malignant Pleural Effusion. Contemporary Medical Symposium. 2014;12(19):255-6.
- 371 doi: 10.3969/j.issn.2095-7629.2014.19.221.
- 372 32. Wang Y, Yang H. Effect of Aidi Injection Combined with Cisplatin on Lung Cancer Malignant Pleural
- 373 Effusion. Psychological Doctor. 2017;23(4):136-7.
- 374 33. Wang YF, SW. Luo,Q. Bai,CF. Li,T. Short-term Effect of Pleural Cavity Drainage and Infusion of
- 375 Compound Kushen Injection Combined with Cisplatin in the Treatment of Malignant Pleural Effusion of Lung
- 376 Cancer. World Latest Medicine Information. 2019;19(02):116+21. doi: 10.19613/j.cnki.1671-3141.2019.02.075.
- 377 34. Wu CL, J. Wu,XY. Cheng,DW. Clinical study of Compound Radix Sophorae Flavescentis Injection
- 378 Combined with Cisplatin in Treatment of Malignant Pleural Effusion. Liao-ning Chung I Tsa Chih Liaoning J Tradit
- 379 Chin Med. 2019;46(01):85-7. doi: 10.13192/j.issn.1000-1719.2019.01.029.
- 380 35. Wu MC, YC. Xie, JL. Xie, WM. Effect of intrapleural injection of different drugs in the treatment of pleural
- effusion in patients with lung cancer. Chinese Community Doctors. 2020;36(12):83+5. doi: 10.13192/j. issn.
- 382 1000-1719. 2019. 01. 029.
- 383 36. Yang D. Efficacy Analysis of Cisplatin Chemotherapy Combined with Aidi Injection in the Treatment of
- Lung Cancer Malignant Pleural Effusion, The Medical Forum, 2015;19(28):3937-8.
- 385 37. Yao Y, Xu H. Treatment of 23 Cases of Malignant Pleural Effusion with Central Venous Catheter
- Drainage Combined with Aidi Injection and Cisplatin. Che-chiang I Hsueh Zhejiang Med J. 2008;(08):884-6. doi:
- 387 10.3969/j.issn.1006-2785.2008.08.040.
- 388 38. Zeng JL, SJ. Effect of Chinese Herbal injection Aidi Injection Combined with Cisplatin on Lung Cancer
- 389 MalignantPleural Effusion. Special Health. 2021;(12):61-2.
- 390 39. Zhang SC, WL. Meng, SL. Brucea Javanica Oil Emulsion Combined with Chemotherapy Drugs for the
- 391 Treatment of Malignant Pleural Effusion in Elderly Patients with Lung Cancer. Mod J Integr Tradit Chin West
- 392 Med Hsien Tai Chung Hsi I Chieh Ho Tsa Chih. 2009;18(15):1749-50. doi: 10.3969/j.issn.1008-
- 393 8849.2009.15.026.
- 394 40. Zhu X. Short-term Efficacy and Nursing Strategies of Pleural Cavity Drainage and Infusion of Compound
- 395 Kushen Injection Combined with Cisplatin in the Treatment of Malignant Pleural Effusion of Lung Cancer.
- 396 Electronic Journal of Practical Clinical Nursing Science. 2018;3(30):151+3. doi: 10.3969/j.issn.2096-


2479.2018.30.123. Wang, XH. Clinical Observation of Aidi Injectio Combined with Cisplatin in the Treatment of Lung Cancer Malignant Pleural Effusion. China Health Care. 2019;18(3):116-117. Xu YF, Chen YR, Bu FL, Huang YB, Sun YX, Li CY, et al. Chinese herbal injections versus intrapleural cisplatin for lung cancer patients with malignant pleural effusion: A Bayesian network meta-analysis of randomized controlled trials. Front Oncol. 2022;12:942941. Epub 2022/10/08. doi: 10.3389/fonc.2022.942941. PubMed PMID: 36203451; PubMed Central PMCID: PMCPMC9531116. 























Liu.D (2015)

Wang, Y (2019)

Wang.HM (2007)

Zhang.SF (2009)

Shen, St. (2017)

HuJC (2008)

Liu,SY (2017)

Chen,F (2018)

0.59 0.60

0.440.47

0.65

0.89

1.00

Han,ZQ (2012)

Shi,WJ (2017)

Tang,XQ (2018)

Wang.HM (2007)

Zhang.SF (2009)

Shen, SL (2017)

HuJC (2008)

Liu.SY (2017)

0.40

0.43

0.50

Wu,CY (2019)

Liu,L (2017)

Liu.D (2015)

Liu.L (2017)

SN,WJ (2017)

Tang,XQ (2018)

Wang, Y (2019)

Wu,CY (2019)

Wang.HM (2007)

Zhang,SF (2009)

Shen,SL (2017)

Hu.JC (2008)


Liu.SY (2017)

0.45 0.48

0.56

0.67

0.73



-.5

-1

s.e. of: theta, filled

0

-.5

.2 s.e. of: logor

# Identification of studies via databases and registers




Figure.1